Table 1 Baseline characteristics of treatment groups.
Tranexamic acid | P | ||
|---|---|---|---|
TA1 group (40-0 mg/Kg) (n = 80) | TA2 group 40-40 mg/Kg (n = 80) | ||
Demographics | |||
Age (years) | 65 (62-69) | 68 (65-70) | 0.24 |
Male sex, n (%) | 54 (67.5) | 49 (61.3) | 0.41 |
Parsonnet | 9.2 (7.2-11.2) | 10.5 (8.4-12.5) | 0.30 |
Euroscorea | 4 (3-6) | 4 (3-7) | 0.38 |
Logistic Euroscorea | 3.25(1.83-5.53) | 3.27(1.75-6.68) | 0.84 |
Body mass index (Kg/m2) | 28.2 (27.4-29) | 27.7 (26.6-28.8) | 0.50 |
Comorbidity | |||
Hypertension, n (%) | 43 (53.8) | 53 (66.3) | 0.11 |
Diabetes, n (%) | 36 (45) | 28 (35) | 0.42 |
Medical treatment | |||
Angiotensin-converting enzyme inhibitors, n (%) | 28 (35) | 22 (27.5) | 0.31 |
Preoperative parameters | |||
Platelet count (× 103 ml-1) | 247 (227-267) | 262 (239-285) | 0.48 |
D-dimer (ng/ml) | 347 (217-476) | 287 (221-353) | 0.95 |
International normalized ratio | 1.04 (1-1.07) | 1.05 (1.01-1.09) | 0.28 |
Cardiac intervention | |||
Coronary, n (%) | 45 (56.3) | 39 (48.8) | 0.51 |
Valvular, n (%) | 25 (31.3) | 31 (38.8) | |
Both, n (%) | 9 (11.3) | 7 (8.8) | |
Other, n (%)b | 1 (1.3) | 3 (3.8) | |
Second intervention, n (%) | 4 (5) | 3 (3.8) | 0.51 |
Surgical data | |||
Temperature during cardiopulmonary bypass (°C) | 32.3 (32-32.5) | 32.3 (32.1-32.5) | 0.78 |
Aortic clamp time (min) | 53 (49-58) | 51 (46-57) | 0.61 |
Cardiopulmonary bypass time(min) | 88 (82-94) | 84 (77-92) | 0.45 |
Temperature after cardiopulmonary bypass (°C) | 35.5 (35.3-35.6) | 35.7 (35.5-35.8) | 0.03 |
Total heparin dose (UI/Kg) | 391 (371-412) | 400 (379-421) | 0.56 |
Total protamine dose (mg/Kg) | 2.7 (2.6-2.8) | 2.9 (2.8-3.1) | 0.04 |
Heparine/protamine | 1.45 (1.37-1.53) | 1.39 (1.33-1.44) | 0.29 |
Blood salvage (ml) | 724 (663-784) | 703 (636-767) | 0.64 |